Hengrui Pharma
Hengrui and Glenmark Strike $1.1B+ ADC Deal for Trastuzumab Rezetecan (SHR-A1811)
Hengrui Pharma signed an exclusive license deal worth up to $1.1B with Glenmark Pharmaceuticals for Trastuzumab Rezetecan (SHR-A1811), its HER2-targeted ADC. The deal underscores China’s growing global impact in ADC innovation while giving Glenmark an emerging-market oncology play.